Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer

Japanese Journal of Clinical Oncology

Volumn 41, Issue 7, 2011, Pages 867-875

  Iwata, Hiroji ^a   Sato, Nobuaki ^b   Masuda, Norikazu ^c   Nakamura, Seigo ^d   Yamamoto, Naohito ^e   Kuroi, Katsumasa ^f   Kurosumi, Masafumi ^g   Tsuda, Hitoshi ^h   Akiyama, Futoshi ⁱ   Ohashi, Yasuo ^j   Toi, Masakazu ^k  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NIIGATA CANCER CENTER HOSPITAL   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^e CHIBA CANCER CENTER   (Japan)

^f TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^g SAITAMA CANCER CENTER   (Japan)

^h NATIONAL CANCER CENTER HOSPITAL   (Japan)

ⁱ CANCER CHEMOTHERAPY CENTER   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

^k KYOTO UNIVERSITY   (Japan)

more..

Author keywords

Breast neoplasms; Docetaxel; FEC protocol; Neoadjuvant therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GRANISETRON; PROGESTERONE RECEPTOR;

ADULT; ALLERGY; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BODY WEIGHT; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MENOPAUSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NAUSEA; NEUTROPENIA; OPEN STUDY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; RASH; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 79960074253     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr081     Document Type: Article

References (29)

1. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9.
2. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006;24:1940-9.
3. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-83.
4. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999;10:47-52.
5. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-66.
6. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
7. Bear HD, Anderson S, Smith RE, Geyer CE, Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019-27.
8. Morrow M, Krontiras H. Who should not receive chemotherapy? Data from American databases and trials. J Natl Cancer Inst Monogr 2001;30:109-3.
9. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
10. Ferriere JP, Assier I, Cure H, Charrier S, Kwiatkowski F, Achard JL, et al. Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome. Am J Clin Oncol 1998;21:117-20.
11. Machiavelli MR, Romero AO, Perez JE, Lacava JA, Dominguez ME, Rodriguez R, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998;4:125-31.
12. Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, et al. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J 2001;7:413-20.
13. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.
14. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005;23:1169-77.
15. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-93.
16. Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U, et al. Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002;359:131-2.
17. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-93.
18. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project rotocol B-27. J Clin Oncol 2003;21:4165-74.
19. Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, et al. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 2008;110:531-9.
20. Japanese Breast Cancer Society. General Rules for Clinical and Pathological Recording of Breast Cancer. 15th edn. Tokyo, Japan: Kanehara Shuppan, 2004; 7.
21. Sakamoto G, Inaji H, Akiyama F, Haga S, Hiraoka M, Inai K, et al. General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer 2005;12(Suppl):S1-27.
22. Wildiers H, Forceville K, Paridaens R, Joensuu H. Taxanes and anthracyclines in early breast cancer: which first?. Lancet Oncol 2010;11:219-20.
23. Simon R, Norton L. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol 2006;3:406-7.
24. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228-33.
25. Gradishar WJ. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology (Williston Park) 1997;11:15-8.
26. Amat S, Bougnoux P, Penault-Llorca F, Cure H, Charrier S, Praagh IV, et al. Primary chemotherapy for operable breast cancer: high pathological response rate induced by docetaxel. Proc Am Soc Clin Oncol 2000;19(Suppl):128a.[Abstract 500].
27. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
28. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008;14:8010-8.
29. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368-76.